Scientific Evidence
Independent validation of TissueCypher to predict progression in community- based Barrett's esophagus with low grade dysplasia: analysis in a completed prospective study
May 2020
TissueCypher stratified BE patients with a community-based diagnosis of LGD with diagnostic accuracy comparable to three renowned expert pathologists.
Publication: Podium presentation (1085) at DDW 2020, Virtual
Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher
May 2020
TissueCypher provided superior risk stratification that outperformed crypt atypia scores.
Publication: Poster presentation (Sa1203) at DDW 2020, Virtual
Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis
May 2020
An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.
Publication: Poster presentation (Sa1189) at DDW 2020, Virtual
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be a effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus
Oct 2019
The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.
Publication: ClinicoEconomics and Outcomes Research
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (P1990) at UEG 2019, Barcelona
A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus
Oct 2019
The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.
Publication: ClinicoEconomics and Outcomes Research
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be an effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
Independent validation of a tissue systems pathology test to predict progression in Barrett’s esophagus patients
May 2019
TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.
Publication: Podium presentation (1068) at DDW 2019, San Diego
Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience
Jun 2018
Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.
Publication: Poster presentation (Su1109) at DDW 2018, Washington DC